BR112016012158A2 - métodos de tratamento e prevenção da doença do enxerto contra o hospedeiro crônica dirigida a aloanticorpo - Google Patents

métodos de tratamento e prevenção da doença do enxerto contra o hospedeiro crônica dirigida a aloanticorpo

Info

Publication number
BR112016012158A2
BR112016012158A2 BR112016012158A BR112016012158A BR112016012158A2 BR 112016012158 A2 BR112016012158 A2 BR 112016012158A2 BR 112016012158 A BR112016012158 A BR 112016012158A BR 112016012158 A BR112016012158 A BR 112016012158A BR 112016012158 A2 BR112016012158 A2 BR 112016012158A2
Authority
BR
Brazil
Prior art keywords
alloantibody
chronic
prevention
directed
treatment
Prior art date
Application number
BR112016012158A
Other languages
English (en)
Portuguese (pt)
Inventor
R Blazar Bruce
Flynn Ryan
Original Assignee
Pharmacyclics Llc
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc, Univ Minnesota filed Critical Pharmacyclics Llc
Publication of BR112016012158A2 publication Critical patent/BR112016012158A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
BR112016012158A 2013-12-02 2014-12-02 métodos de tratamento e prevenção da doença do enxerto contra o hospedeiro crônica dirigida a aloanticorpo BR112016012158A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910944P 2013-12-02 2013-12-02
US201461973178P 2014-03-31 2014-03-31
PCT/US2014/068177 WO2015084857A1 (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease

Publications (1)

Publication Number Publication Date
BR112016012158A2 true BR112016012158A2 (pt) 2017-09-26

Family

ID=53270044

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016012158A BR112016012158A2 (pt) 2013-12-02 2014-12-02 métodos de tratamento e prevenção da doença do enxerto contra o hospedeiro crônica dirigida a aloanticorpo

Country Status (14)

Country Link
US (5) US20150157634A1 (enExample)
EP (1) EP3076975A4 (enExample)
JP (5) JP2017501140A (enExample)
KR (2) KR20230104754A9 (enExample)
CN (2) CN110478353B (enExample)
AU (4) AU2014360758B2 (enExample)
BR (1) BR112016012158A2 (enExample)
CA (2) CA3210338A1 (enExample)
EA (1) EA201691020A1 (enExample)
IL (4) IL292522A (enExample)
MX (2) MX389020B (enExample)
PH (2) PH12020552048A1 (enExample)
TW (3) TWI743019B (enExample)
WO (1) WO2015084857A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI662963B (zh) 2012-06-04 2019-06-21 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
EP3060218A4 (en) 2013-10-25 2017-07-19 Pharmacyclics LLC Methods of treating and preventing graft versus host disease
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
EP3432879B1 (en) 2016-03-22 2021-01-06 Mayo Foundation for Medical Education and Research Using fatty acid synthase inhibitors to treat fibrosis
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
US20200054721A1 (en) * 2016-10-21 2020-02-20 Bruce R. Blazar Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US20240025990A1 (en) * 2020-12-01 2024-01-25 City Of Hope Prevention and treatment of graft-versus-host disease (gvhd)
US20240139195A1 (en) * 2021-01-30 2024-05-02 Beigene Switzerland Gmbh Methods of treating chronic active antibody-mediated rejection using btk inhibitors
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
KR20080098490A (ko) * 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
SG166093A1 (en) * 2006-09-22 2010-11-29 Pharmacyclics Inc Inhibitors of brutonæs tyrosine kinase
CA2730930C (en) * 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
EP2424368B1 (en) * 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CA2772199A1 (en) * 2009-08-31 2011-03-03 Amplimmune, Inc. B7-h4 fusion proteins and methods of use thereof
NZ717373A (en) * 2010-06-03 2017-11-24 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CA2841111A1 (en) * 2011-07-08 2013-01-17 Novartis Ag Novel pyrrolo pyrimidine derivatives
US9522917B2 (en) * 2012-04-11 2016-12-20 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
DK2854850T3 (da) * 2012-05-25 2021-08-30 Sloan Kettering Inst Cancer Res Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
EP3060218A4 (en) * 2013-10-25 2017-07-19 Pharmacyclics LLC Methods of treating and preventing graft versus host disease
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
KR20230104754A9 (ko) 2024-11-15
CN110478353A (zh) 2019-11-22
US20230100137A1 (en) 2023-03-30
CN105939717B (zh) 2019-09-13
KR20160085817A (ko) 2016-07-18
TWI743019B (zh) 2021-10-21
US20210177854A1 (en) 2021-06-17
IL315228A (en) 2024-10-01
MX389020B (es) 2025-03-20
CN105939717A (zh) 2016-09-14
CN110478353B (zh) 2022-12-30
TW202402295A (zh) 2024-01-16
JP2023029899A (ja) 2023-03-07
CA3210338A1 (en) 2015-06-11
JP2025118595A (ja) 2025-08-13
CA2932255C (en) 2023-10-10
MX2016006955A (es) 2016-09-07
MX2022000209A (es) 2022-02-03
US20240293409A1 (en) 2024-09-05
AU2020204276A1 (en) 2020-07-16
PH12016501051A1 (en) 2016-08-15
WO2015084857A1 (en) 2015-06-11
AU2022203810B2 (en) 2024-10-03
EP3076975A1 (en) 2016-10-12
PH12020552048A1 (en) 2022-05-11
US20150157634A1 (en) 2015-06-11
AU2024278490A1 (en) 2025-01-09
EA201691020A1 (ru) 2017-01-30
IL245715A0 (en) 2016-07-31
CA2932255A1 (en) 2015-06-11
JP2017501140A (ja) 2017-01-12
AU2014360758B2 (en) 2020-03-26
JP2020105181A (ja) 2020-07-09
AU2014360758A1 (en) 2016-06-16
AU2022203810A1 (en) 2022-06-23
TW201605454A (zh) 2016-02-16
TW202228700A (zh) 2022-08-01
EP3076975A4 (en) 2017-05-03
JP2024072291A (ja) 2024-05-27
IL292522A (en) 2022-06-01
IL276683A (en) 2020-09-30
KR20230104754A (ko) 2023-07-10
US20180078558A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
BR112016012158A2 (pt) métodos de tratamento e prevenção da doença do enxerto contra o hospedeiro crônica dirigida a aloanticorpo
IL284727B (en) Noise suppression methods and apparatus
IL245183A0 (en) Methods for the treatment and prevention of an implant against surrogate disease
LT2943192T (lt) Kasos vėžio gydymo būdai, apimantys paklitakselį ir gemcitabiną
IL239735A0 (en) Treatment and diseases associated with toxic aldehyde
EP3620203C0 (en) VASCULAR TREATMENT DEVICES
IL249065A0 (en) Combination therapies for the treatment of cancer
EP3122414A4 (en) Venous disease treatment
EP3104817C0 (en) SYSTEMS AND METHODS FOR TISSUE HEALING
SI3033086T1 (sl) Kombinirana terapija za zdravljenje raka
EP2970312A4 (en) BET-BROMDOMÄNENHEMMER AND THERAPEUTIC PROCESSES THEREWITH
EP2968191A4 (en) METHOD FOR THE TREATMENT OF BUBBLE CANCER
SG11201708075RA (en) Treatment of chronic graft versus host disease with syk inhibitors
PT3626270T (pt) Tratamento de doenças cardiovasculares
LT3007726T (lt) Tautopatijos gydymo būdai
HRP20182138T1 (hr) Modificirani serpini za liječenje poremećaja s krvarenjem
HRP20180337T1 (hr) Kalcitonin mimetika za liječenje bolesti i poremećaja
HUE054330T2 (hu) Graft versus host betegség kezelése transzplantációs betegekben
SG11201701493VA (en) Systems level state characteristics in experimental treatment of disease
MA40687A (fr) Méthodes et compositions de traitement de malformation vasculaire
PL2948137T3 (pl) Sposoby leczenia zwłóknienia i nowotworów
FR3011165B3 (fr) Chaussure therapeutique modifiable multifonction
EP2964227A4 (en) TREATMENT AND PROPHYLAXIS OF RENAL DISEASES
DK2976101T3 (da) Behandlingsfremgangsmåde
IL252779A0 (en) Prevention and treatment of inflammatory conditions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: PHARMACYCLICS LLC (US) ; REGENTS OF THE UNIVERSITY OF MINNESOTA (US)